Millennium group reports 2.5% ARS Pharmaceuticals stake

Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander filed Amendment No. 2 to a Schedule 13G reporting their beneficial ownership of ARS Pharmaceuticals, Inc. common stock.

Rhea-AI Filing Summary

Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander filed Amendment No. 2 to a Schedule 13G reporting their beneficial ownership of ARS Pharmaceuticals, Inc. common stock.

Integrated Core Strategies (US) LLC reports shared voting and dispositive power over 1,336,609 shares, representing 1.3% of the common stock. Millennium Management LLC, Millennium Group Management LLC and Mr. Englander each report shared voting and dispositive power over 2,520,937 shares, representing 2.5% of the class. The filing states that the reporting persons have ownership of 5 percent or less of the class and includes customary disclaimers regarding beneficial ownership of securities held by managed entities.

Key Figures

Integrated Core Strategies shares: 1,336,609 shares Integrated Core Strategies ownership: 1.3% Millennium/Englander shares: 2,520,937 shares +1 more

4 metrics

Integrated Core Strategies shares 1,336,609 shares Shared voting and dispositive power over ARS Pharmaceuticals common stock

Integrated Core Strategies ownership 1.3% Percent of ARS Pharmaceuticals common stock class

Millennium/Englander shares 2,520,937 shares Shared voting and dispositive power over ARS Pharmaceuticals common stock

Millennium/Englander ownership 2.5% Percent of ARS Pharmaceuticals common stock class

Key Terms

Schedule 13G, beneficially owned, shared voting power, shared dispositive power, +1 more

5 terms

Schedule 13G regulatory

"filed Amendment No. 2 to a Schedule 13G reporting their beneficial ownership"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficially owned financial

"Amount beneficially owned: See response to Item 9 on each cover page"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared voting power financial

"Shared Voting Power 1,336,609.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"Shared Dispositive Power 2,520,937.00"

joint filing agreement regulatory

"Exhibit I: Joint Filing Agreement, dated as of July 13, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake in ARS Pharmaceuticals (SPRY) does Integrated Core Strategies (US) LLC report?

Integrated Core Strategies (US) LLC reports beneficial ownership of 1,336,609 ARS Pharmaceuticals common shares, with 1.3% of the class. It has shared voting and dispositive power over these shares and reports no sole voting or dispositive authority.

How many ARS Pharmaceuticals (SPRY) shares do the Millennium entities and Israel A. Englander report?

Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 2,520,937 ARS Pharmaceuticals common shares. This represents 2.5% of the outstanding common stock, with shared voting and dispositive power and no sole authority.

What does the ARS Pharmaceuticals (SPRY) Schedule 13G/A say about ownership levels?

The Schedule 13G/A states that the reporting persons have ownership of 5 percent or less of ARS Pharmaceuticals’ common stock. Individual cover pages show positions of 1.3% and 2.5% of the class for the respective reporting entities.

Do the SPRY reporting persons have sole or shared voting power over the shares?

The reporting persons disclose 0 sole voting power and 0 sole dispositive power over ARS Pharmaceuticals shares. All reported authority relates to shared voting and shared dispositive power over the indicated share amounts for each entity.

How does the filing describe beneficial ownership for SPRY shares managed by Millennium?

The filing explains that securities are held by entities subject to voting control and investment discretion by Millennium Management LLC and other managers. It notes this should not alone be construed as an admission of beneficial ownership by Millennium entities or Mr. Englander.

Who signed the ARS Pharmaceuticals (SPRY) Schedule 13G/A Amendment No. 2?

The amendment is signed by Gil Raviv, Global General Counsel, on behalf of several entities, and by Israel A. Englander individually. The signatures are dated July 13, 2026, and a joint filing agreement among the reporting persons is included as an exhibit.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/14/2026 - 05:47 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

ARS Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

82835W108

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 82835W108

1

Names of Reporting Persons

Integrated Core Strategies (US) LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,336,609.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,336,609.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,336,609.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.3 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 82835W108

1

Names of Reporting Persons

Millennium Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,520,937.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,520,937.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,520,937.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.5 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 82835W108

1

Names of Reporting Persons

Millennium Group Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,520,937.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,520,937.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,520,937.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.5 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 82835W108

1

Names of Reporting Persons

Israel A. Englander

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,520,937.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,520,937.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,520,937.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.5 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ARS Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 11682 El Camino Real, Suite 300, San Diego, California 92130
Item 2.
(a)	Name of person filing: Integrated Core Strategies (US) LLC Millennium Management LLC Millennium Group Management LLC Israel A. Englander
(b)	Address or principal business office or, if none, residence: Integrated Core Strategies (US) LLC c/o Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
(c)	Citizenship: Integrated Core Strategies (US) LLC - Delaware Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 82835W108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to Item 9 on each cover page.
(b)	Percent of class: See response to Item 11 on each cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to Item 5 on each cover page.
	(ii) Shared power to vote or to direct the vote: See response to Item 6 on each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to Item 7 on each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Integrated Core Strategies (US) LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	07/13/2026

Millennium Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	07/13/2026

Millennium Group Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	07/13/2026

Israel A. Englander

Signature:	/s/ Israel A. Englander
Name/Title:	Israel A. Englander
Date:	07/13/2026

Comments accompanying signature: ** INTEGRATED CORE STRATEGIES (US) LLC By: Integrated Holding Group LP, its Managing Member By: Millennium Management LLC, its General Partner

Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of July 13, 2026, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.